Prostate cancer (PC) remains a relevant problem in urological oncology practice because of the high incidence of this disease. Palliative hormone therapy is a basic therapy option for patients with metastatic PC. Chemotherapy or second-line hormone therapy, as well as therapy aimed at inhibiting the so-called ligand-dependent androgen receptor activity may be performed in the progression and development of castration-refractory PC. The paper reviews the results of present-day investigations evaluating the efficacy of insulin-like growth factor inhibitors, the Depot long-acting somatostatin analog octreotide.